EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report)'s stock price gapped up before the market opened on Tuesday . The stock had previously closed at $8.90, but opened at $9.35. EyePoint Pharmaceuticals shares last traded at $9.43, with a volume of 96,774 shares traded.
Analyst Upgrades and Downgrades
EYPT has been the topic of several research analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $22.00 price objective on shares of EyePoint Pharmaceuticals in a research note on Thursday, May 29th. Chardan Capital cut their price objective on EyePoint Pharmaceuticals from $33.00 to $27.00 and set a "buy" rating for the company in a report on Thursday, May 8th. Wall Street Zen raised shares of EyePoint Pharmaceuticals to a "sell" rating in a research report on Friday, March 14th. Mizuho cut their target price on EyePoint Pharmaceuticals from $30.00 to $26.00 and set an "outperform" rating for the company in a research note on Friday, May 16th. Finally, Royal Bank of Canada assumed coverage on shares of EyePoint Pharmaceuticals in a research report on Tuesday. They set an "outperform" rating and a $28.00 price target for the company. One research analyst has rated the stock with a sell rating and ten have given a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $25.67.
Check Out Our Latest Research Report on EyePoint Pharmaceuticals
EyePoint Pharmaceuticals Stock Performance
The stock has a 50 day moving average of $6.63 and a 200-day moving average of $6.90. The company has a market cap of $624.46 million, a PE ratio of -4.54 and a beta of 1.61.
EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported ($0.65) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.65). The business had revenue of $24.50 million during the quarter, compared to analyst estimates of $8.84 million. EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. Equities research analysts forecast that EyePoint Pharmaceuticals, Inc. will post -2.13 EPS for the current year.
Institutional Investors Weigh In On EyePoint Pharmaceuticals
A number of large investors have recently bought and sold shares of the stock. Suvretta Capital Management LLC grew its position in shares of EyePoint Pharmaceuticals by 31.1% in the 4th quarter. Suvretta Capital Management LLC now owns 6,783,091 shares of the company's stock worth $50,534,000 after buying an additional 1,607,268 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its stake in shares of EyePoint Pharmaceuticals by 7.8% in the first quarter. Adage Capital Partners GP L.L.C. now owns 6,200,000 shares of the company's stock worth $33,604,000 after purchasing an additional 450,000 shares during the last quarter. Franklin Resources Inc. raised its stake in EyePoint Pharmaceuticals by 3.1% in the 4th quarter. Franklin Resources Inc. now owns 4,137,567 shares of the company's stock valued at $30,825,000 after purchasing an additional 125,519 shares during the last quarter. Federated Hermes Inc. boosted its stake in shares of EyePoint Pharmaceuticals by 10.2% in the first quarter. Federated Hermes Inc. now owns 4,085,580 shares of the company's stock valued at $22,144,000 after purchasing an additional 378,135 shares during the period. Finally, Vanguard Group Inc. grew its stake in EyePoint Pharmaceuticals by 0.8% during the 1st quarter. Vanguard Group Inc. now owns 3,834,368 shares of the company's stock worth $20,782,000 after buying an additional 31,141 shares during the last quarter. 99.41% of the stock is currently owned by institutional investors and hedge funds.
About EyePoint Pharmaceuticals
(
Get Free Report)
EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider EyePoint Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and EyePoint Pharmaceuticals wasn't on the list.
While EyePoint Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
